152 related articles for article (PubMed ID: 9466652)
21. Characterization of IgA response among women with incident HPV 16 infection.
Onda T; Carter JJ; Koutsky LA; Hughes JP; Lee SK; Kuypers J; Kiviat N; Galloway DA
Virology; 2003 Jul; 312(1):213-21. PubMed ID: 12890634
[TBL] [Abstract][Full Text] [Related]
22. Human papillomavirus (HPV) and Epstein-Barr virus (EBV) cervical infections in women with normal and abnormal cytology.
Szkaradkiewicz A; Wal M; Kuch A; Pieta P
Pol J Microbiol; 2004; 53(2):95-9. PubMed ID: 15478354
[TBL] [Abstract][Full Text] [Related]
23. Human papillomavirus infection and time to progression and regression of cervical intraepithelial neoplasia.
Schlecht NF; Platt RW; Duarte-Franco E; Costa MC; Sobrinho JP; Prado JC; Ferenczy A; Rohan TE; Villa LL; Franco EL
J Natl Cancer Inst; 2003 Sep; 95(17):1336-43. PubMed ID: 12953088
[TBL] [Abstract][Full Text] [Related]
24. Conization for cervical intraepithelial neoplasia is followed by disappearance of human papillomavirus deoxyribonucleic acid and a decline in serum and cervical mucus antibodies against human papillomavirus antigens.
Elfgren K; Bistoletti P; Dillner L; Walboomers JM; Meijer CJ; Dillner J
Am J Obstet Gynecol; 1996 Mar; 174(3):937-42. PubMed ID: 8633673
[TBL] [Abstract][Full Text] [Related]
25. Specific serum IgG, IgM and IgA antibodies to human papillomavirus types 6, 11, 16, 18 and 31 virus-like particles in human immunodeficiency virus-seropositive women.
Petter A; Heim K; Guger M; Ciresa-Kö Nig A; Christensen N; Sarcletti M; Wieland U; Pfister H; Zangerle R; Höpfl R
J Gen Virol; 2000 Mar; 81(Pt 3):701-8. PubMed ID: 10675407
[TBL] [Abstract][Full Text] [Related]
26. Serum antibodies to human papillomavirus 16 proteins in women from Brazil with invasive cervical carcinoma.
Sun Y; Eluf-Neto J; Bosch FX; Muñoz N; Walboomers JM; Meijer CJ; Shah KV; Clayman B; Viscidi RP
Cancer Epidemiol Biomarkers Prev; 1999 Oct; 8(10):935-40. PubMed ID: 10548324
[TBL] [Abstract][Full Text] [Related]
27. Seric and local antibodies against a synthetic peptide of HPV16.
Dreyfus M; Baldauf JJ; Ritter J; Obert G
Eur J Obstet Gynecol Reprod Biol; 1995 Apr; 59(2):187-91. PubMed ID: 7657014
[TBL] [Abstract][Full Text] [Related]
28. Serologic response to human oncogenic papillomavirus types 16, 18, 31, 33, 39, 58 and 59 virus-like particles in colombian women with invasive cervical cancer.
Combita AL; Bravo MM; Touzé A; Orozco O; Coursaget P
Int J Cancer; 2002 Feb; 97(6):796-803. PubMed ID: 11857357
[TBL] [Abstract][Full Text] [Related]
29. A survey on the prevalence of high-risk subtypes of human papilloma virus among women with cervical neoplasia in Isfahan University of Medical Science.
Allameh T; Moghim S; Asadi-Zeidabadi M
Arch Gynecol Obstet; 2011 Dec; 284(6):1509-13. PubMed ID: 21387088
[TBL] [Abstract][Full Text] [Related]
30. Different risk factor patterns for high-grade and low-grade intraepithelial lesions on the cervix among HPV-positive and HPV-negative young women.
Krüger-Kjaer S; van den Brule AJ; Svare EI; Engholm G; Sherman ME; Poll PA; Walboomers JM; Bock JE; Meijer CJ
Int J Cancer; 1998 May; 76(5):613-9. PubMed ID: 9610715
[TBL] [Abstract][Full Text] [Related]
31. Natural history of human papillomavirus type 16 virus-like particle antibodies in young women.
Ho GY; Studentsov YY; Bierman R; Burk RD
Cancer Epidemiol Biomarkers Prev; 2004 Jan; 13(1):110-6. PubMed ID: 14744741
[TBL] [Abstract][Full Text] [Related]
32. Prevalence of human papillomavirus genotypes, and mucosal IgA anti-viral responses in women with cervical ectopy.
Monroy OL; Aguilar C; Lizano M; Cruz-Talonia F; Cruz RM; Rocha-Zavaleta L
J Clin Virol; 2010 Jan; 47(1):43-8. PubMed ID: 19906557
[TBL] [Abstract][Full Text] [Related]
33. Antibodies to human papillomavirus 16, 18, 58, and 6b major capsid proteins among Japanese females.
Matsumoto K; Yoshikawa H; Taketani Y; Yoshiike K; Kanda T
Jpn J Cancer Res; 1997 Apr; 88(4):369-75. PubMed ID: 9197528
[TBL] [Abstract][Full Text] [Related]
34. Multiple human papillomavirus infections with high viral loads are associated with cervical lesions but do not differentiate grades of cervical abnormalities.
Schmitt M; Depuydt C; Benoy I; Bogers J; Antoine J; Arbyn M; Pawlita M;
J Clin Microbiol; 2013 May; 51(5):1458-64. PubMed ID: 23447632
[TBL] [Abstract][Full Text] [Related]
35. Analysis of IgG reactivity against Human Papillomavirus type-16 E7 in patients with cervical intraepithelial neoplasia indicates an association with clearance of viral infection: results of a prospective study.
de Gruijl TD; Bontkes HJ; Walboomers JM; Stukart MJ; Robbesom AA; von Blomberg-van der Flier BM; Herbrink P; Remmink AJ; Verheijen RH; Helmerhorst TJ; Meijer CJ; Scheper RJ
Int J Cancer; 1996 Dec; 68(6):731-8. PubMed ID: 8980175
[TBL] [Abstract][Full Text] [Related]
36. A population-based seroepidemiological study of cervical cancer.
Dillner J; Lenner P; Lehtinen M; Eklund C; Heino P; Wiklund F; Hallmans G; Stendahl U
Cancer Res; 1994 Jan; 54(1):134-41. PubMed ID: 8261434
[TBL] [Abstract][Full Text] [Related]
37. Increased secretion patterns of interleukin-10 and tumor necrosis factor-alpha in cervical squamous intraepithelial lesions.
Azar KK; Tani M; Yasuda H; Sakai A; Inoue M; Sasagawa T
Hum Pathol; 2004 Nov; 35(11):1376-84. PubMed ID: 15668895
[TBL] [Abstract][Full Text] [Related]
38. Differences in serological IgA responses to recombinant baculovirus-derived human papillomavirus E2 protein in the natural history of cervical neoplasia.
Rocha-Zavaleta L; Jordan D; Pepper S; Corbitt G; Clarke F; Maitland NJ; Sanders CM; Arrand JR; Stern PL; Stacey SN
Br J Cancer; 1997; 75(8):1144-50. PubMed ID: 9099962
[TBL] [Abstract][Full Text] [Related]
39. Profiling of serum antibodies against human papillomavirus antigens in Korean women with cervical intraepithelial neoplasia and cervical cancer.
Jin Y; Choi JW; Kim HJ; Eddouzi J; Kim SC; Ju W; Kim YH; Kim HJ
Cancer Med; 2018 Nov; 7(11):5655-5664. PubMed ID: 30353680
[TBL] [Abstract][Full Text] [Related]
40. Serum immunoglobulin A response to human papillomavirus type 16 virus-like particles in human immunodeficiency virus (HIV)-positive and high-risk HIV-negative women.
Viscidi RP; Ahdieh-Grant L; Schneider MF; Clayman B; Massad LS; Anastos KM; Burk RD; Minkoff H; Palefsky J; Levine A; Strickler H
J Infect Dis; 2003 Dec; 188(12):1834-44. PubMed ID: 14673762
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
